Evidence map›Paper›PMID 24689659›Full record

ReviewExpert review of vaccines2014

Current trends in West Nile virus vaccine development.

Ian J Amanna, Mark K Slifka

Abstract readReview
In one paragraph

Review in Expert review of vaccines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 56 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Targeting the protease of West Nile virus.RSC medicinal chemistry · 2021
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Frontiers in cellular and infection microbiology · 2019
    Review
  19. Key Factors Influencing the Incidence of West Nile Virus in Burleigh County, North Dakota.International journal of environmental research and public health · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ian J AmannaNajít Technologies, Inc., 505 NW 185th Avenue, Beaverton, OR 97006, USA.
Mark K Slifka
Najít Technologies (United States) · USOregon National Primate Research Center · US

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Development of an H2O2-Inactivated Dengue Virus VaccineR01AI098723 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SLIFKA, MARK K · 2012 to 2016
$7.3M
Development of a Safe and Effective Vaccine Against West Nile VirusU01AI082196 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SLIFKA, MARK K · 2009 to 2012
$7.1M
Development of a Yellow Fever Vaccine for Vulnerable PopulationR44AI079898 · NIAID · NAJIT TECHNOLOGIES, INC. · PI AMANNA, IAN JAMES, SLIFKA, MARK K · 2011 to 2020
$6.2M
NIAID NIH HHS R01 AI098723NIAID NIH HHS R44 AI079898NIAID NIH HHS U01 AI082196NIH HHS 8P51 OD011092-53NIH HHS P51 OD011092
6 · The paper itself

Abstract

West Nile virus (WNV) is a mosquito-borne flavivirus that has become endemic in the United States. From 1999-2012, there have been 37088 reported cases of WNV and 1549 deaths, resulting in a 4.2% case-fatality rate. Despite development of effective WNV vaccines for horses, there is no vaccine to prevent human WNV infection. Several vaccines have been tested in preclinical studies and to date there have been eight clinical trials, with promising results in terms of safety and induction of antiviral immunity. Although mass vaccination is unlikely to be cost effective, implementation of a targeted vaccine program may be feasible if a safe and effective vaccine can be brought to market. Further evaluation of new and advanced vaccine candidates is strongly encouraged.

Indexed as

West Nile virusAnimalsHumansImmunization ProgramsWest Nile FeverWest Nile Virus VaccinesWest Nile Virus Vaccines

Identifiers

PMID24689659
PMCPMC4279923
OpenAlexW2120073428

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.